经尿道膀胱肿瘤电切术联合表柔比星膀胱热灌注化疗治疗非肌层浸润性膀胱癌对预后的影响  

The Impact of Transurethral Resection of Bladder Tumor Combined with Epirubicin Hyperthermic Intravesical Chemotherapy on Prognosis in Non-Muscle-Invasive Bladder Cancer

作　　者：赵刚 裴亚伟 ZHAO Gang;PEI Yawei(Department of Urology,Ulanqab Central Hospital,Ulanqab 012000,China;不详)

机构地区：[1]乌兰察布市中心医院泌尿外科,内蒙古乌兰察布012000

出　　处：《中国医学创新》2025年第9期1-5,共5页Medical Innovation of China

摘　　要：目的:研究非肌层浸润性膀胱癌(NMIBC)患者采用经尿道膀胱肿瘤电切术(TUR-BT)联合表柔比星膀胱热灌注化疗治疗的临床效果。方法:病例为乌兰察布市中心医院泌尿外科收治的122例NMIBC确诊患者,收治入院时间段为2020年1月—2021年5月,行随机对照研究,以病历号单双数为标准分组为研究A组、研究B组,各组均61例患者。研究A组治疗方案为TUR-BT联合表柔比星膀胱热灌注化疗,研究B组治疗方案为TUR-BT联合丝裂霉素膀胱热灌注化疗,对比两组术后复发率、远期生存率、血清肿瘤标志物水平、生存质量评分、不良反应发生率。结果:相较于研究B组,研究A组术后复发率更低,远期生存率更高,差异均有统计学意义(P<0.05);相较于研究B组,术后研究A组血清肿瘤标志物水平均更低,差异均有统计学意义(P<0.05);相较于研究B组,术后研究A组生存质量评分均更高,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:NMIBC患者采用TUR-BT联合表柔比星膀胱热灌注化疗治疗可降低复发率,提高远期生存率,降低血清肿瘤标志物水平,改善生存质量,不良反应发生率较低。Objective:To investigate the clinical effect of transurethral resection of bladder tumor(TUR-BT)combined with Epirubicin in the treatment of non-muscle-invasive bladder cancer(NMIBC).Method:A total of 122 patients diagnosed with NMIBC were admitted to the Department of Urology,Ulanqab Central Hospital from January 2020 to May 2021.A randomized controlled study was conducted.The patients were divided into study group A and study group B based on the even number of medical records,with 61 patients in each group.The treatment regimen of study group A was TUR-BT combined with Epirubicin in bladder hyperperfusion chemotherapy,and the treatment regimen of study group B was TUR-BT combined with Mitomycin in bladder hyperperfusion chemotherapy.Postoperative recurrence rate,long-term survival rate,serum tumor marker levels,quality of life score and incidence of adverse reactions were compared between the two groups.Result:Compared with study group B,study group A had lower postoperative recurrence rate and higher long-term survival rate,with statistical significance(P<0.05).Compared with study group B,the levels of serum tumor markers in postoperative study group A were lower,the differences were statistically significant(P<0.05).Compared with study group B,the quality of life scores of postoperative study group A were higher,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:In NMIBC patients,TUR-BT combined with Epirubicin can reduce the recurrence rate,increase the long-term survival rate,reduce the levels of serum tumor markers,improve the quality of life,and have a lower incidence of adverse reactions.

关 键 词：经尿道膀胱肿瘤电切术 表柔比星 膀胱热灌注化疗 膀胱癌 

分 类 号：R73[医药卫生—肿瘤]